Is Bal Pharma overvalued or undervalued?

Nov 16 2025 08:08 AM IST
share
Share Via
As of November 14, 2025, Bal Pharma is considered an attractive investment due to its undervalued status, with a PE Ratio of 18.76, an EV to EBITDA of 10.07, and a low PEG Ratio of 0.00, especially when compared to more expensive peers like Sun Pharma and Divi's Lab.
As of 14 November 2025, Bal Pharma's valuation grade has moved from very attractive to attractive. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 18.76, an EV to EBITDA of 10.07, and a Price to Book Value of 1.63, which suggest that the stock is trading at a reasonable valuation compared to its earnings and asset base.

In comparison to peers, Bal Pharma's PE Ratio is significantly lower than that of Sun Pharma (36.49) and Divi's Lab (69.65), both of which are categorized as expensive. Additionally, Bal Pharma's PEG Ratio is notably low at 0.00, indicating potential growth opportunities that are not reflected in its current price. While the stock has underperformed against the Sensex over the past year, this valuation suggests that it may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News